In PC3-M prostate cancer cells, curcumin promoted the proteasome-dependent degradation of p300/CBP without affecting the levels of other HATs such as PCAF or GCN5, being proposed as a therapeutic compound to specifically inhibit p300/CBP HAT (191). The gene discussed is KAT2B; the disease is prostate carcinoma.